**Core Concept**
The emergence of New Delhi beta-lactamase (NDM-1) producing bacteria poses a significant challenge in treating infections caused by these strains. NDM-1 is a type of carbapenemase that confers resistance to carbapenem antibiotics, making it essential to have alternative treatment options.

**Why the Correct Answer is Right**
The correct answer is a drug that is not susceptible to degradation by NDM-1. Colistin is a polymyxin antibiotic that has been shown to be effective against NDM-1 producing bacteria. Colistin works by binding to the bacterial cell membrane, disrupting its function, and ultimately leading to cell death. This mechanism of action is not affected by the presence of NDM-1, making colistin a viable treatment option for infections caused by these strains.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it is not a known effective treatment for NDM-1 producing bacteria. While it may have some antimicrobial properties, it is not a reliable option for treating infections caused by these strains.
**Option B:** This option is incorrect because it is also not a known effective treatment for NDM-1 producing bacteria. In fact, carbapenems are often the antibiotics that are degraded by NDM-1, making them ineffective against these strains.
**Option C:** This option is incorrect because it is not a known effective treatment for NDM-1 producing bacteria. While it may have some antimicrobial properties, it is not a reliable option for treating infections caused by these strains.

**Clinical Pearl / High-Yield Fact**
It's essential to note that the emergence of NDM-1 producing bacteria highlights the need for antimicrobial stewardship and the development of new treatment options. Clinicians should be aware of the local resistance patterns and use antibiotics judiciously to prevent the spread of resistance.

**Correct Answer: C. Colistin**